- Mallinckrodt (NYSE:MNK) Q4 results ($M): Net Sales: 829.9 (+2.3%); Specialty Brands: 603.1 (-11.0%); Specialty Generics: 212.9 (-17.4%).
- Net Income: (153.2) (-172.6%); Non-GAAP Net Income: 203.6 (-11.1%); EPS: (1.45) (-179.7%); Non-GAAP EPS: 1.91 (-3.0%); CF Ops: 195.6 (-37.2%).
- Key Product Sales: Acthar: 325.4 (+13.5%), Inomax: 118.3 (+6.8%).
-
2017 Guidance: Sales growth: 2 - 5% decline; Specialty Brands sales: 4 - 7% increase; Specialty Generics sales: 21 - 25% decline; Non-GAAP EPS: $7.40 - 8.00.
- Shares are up a fraction premarket